FHLC or IYH or XLV

Key Takeaways

• FHLC offers the broadest diversification with approximately 340 holdings, including small-cap exposure via the MSCI USA IMI Health Care 25/50 Index (IMI stands for Investable Market Index, covering large, mid, and small caps), at a low expense ratio of 0.08%.
• IYH provides mid-cap tilted exposure through the Russell 1000 Health Care RIC 22.5/45 Capped Index (RIC refers to Risk Control, limiting single-stock and top-heavy concentration), with 103 holdings but a higher expense ratio of 0.38%.
• XLV focuses on large-cap leaders from the S&P 500 via the Health Care Select Sector Index, holding around 60 stocks with the highest concentration risk (top 10 at ~59%) yet matching FHLC's cost efficiency at 0.08% and superior liquidity.
• All three are passive, non-diversified healthcare sector ETFs with nearly 100% sector allocation, differing primarily in market-cap scope and concentration levels.
• FHLC edges in diversification depth and cost-adjusted positioning, while XLV leads in liquidity and AUM (assets under management, total value of fund assets).
• Recent months show similar volatility profiles, with FHLC exhibiting slightly lower fluctuations due to broader holdings.

Introduction

Investors seeking healthcare sector exposure compare FHLC, IYH, and XLV amid ongoing sector resilience driven by innovation in pharmaceuticals and biotech, alongside demographic tailwinds from aging populations. These passive ETFs track U.S. healthcare equities but vary structurally: FHLC captures broad-market including small caps, IYH emphasizes large- and mid-caps with concentration caps, and XLV targets S&P 500 large caps. This comparison highlights differences in diversification, costs, and liquidity, aiding decisions in a market favoring defensive sectors amid economic uncertainty. All offer pure healthcare plays without leverage or thematics, positioning them for long-term sector rotation strategies.

Fidelity MSCI Health Care Index ETF (FHLC) Overview

The Fidelity MSCI Health Care Index ETF (FHLC) seeks investment returns corresponding to the MSCI USA IMI Health Care 25/50 Index, emphasizing broad U.S. healthcare sector performance across market caps. It holds approximately 340 stocks, providing extensive diversification including small caps absent in peers. Top holdings include LLY (11.26%), JNJ (9.02%), ABBV (5.93%), UNH (5.53%), and MRK (4.53%), with top 10 comprising ~50%. Sector allocation is nearly 100% healthcare. The expense ratio is a competitive 0.08%. FHLC uses representative sampling and rebalances with the index, offering liquidity suitable for most investors.

iShares U.S. Healthcare ETF (IYH) Overview

The iShares U.S. Healthcare ETF (IYH) tracks the Russell 1000 Health Care RIC 22.5/45 Capped Index, focusing on large- and mid-cap U.S. healthcare equities with caps to limit concentration (no stock over 22.5%, top quintile aggregate under 45%). It maintains about 103 holdings. Top holdings feature LLY (13.72%), JNJ (10.14%), ABBV (6.86%), UNH (6.18%), and MRK (4.97%), top 10 at ~57%. Allocation is 100% healthcare, with sub-sector weights like pharmaceuticals (~36%), biotech (~22%), and equipment (~17%). Expense ratio stands at 0.38%. Quarterly rebalancing enhances risk control in volatile sub-sectors.

Health Care Select Sector SPDR Fund (XLV) Overview

The Health Care Select Sector SPDR Fund (XLV) corresponds to the Health Care Select Sector Index, comprising large-cap healthcare firms from the S&P 500 in pharmaceuticals, providers, biotech, equipment, and tools. It holds around 60 stocks, emphasizing market leaders. Top holdings: LLY (14.07%), JNJ (10.52%), ABBV (7.10%), UNH (6.38%), MRK (5.15%), top 10 ~59%. Sector is 100% healthcare, with pharmaceuticals (~37%), providers (~19%), and biotech (~18%). Expense ratio is 0.08%. Full replication and quarterly rebalancing support high liquidity, with massive AUM enhancing tradability.

Industry and Thematic Landscape

The U.S. healthcare sector benefits from aging demographics boosting demand for services and therapies, alongside AI-driven efficiencies and outpatient shifts. Capital flows into private equity and biotech reflect optimism, with lower interest rates aiding dealmaking. However, regulatory scrutiny via drug pricing reforms, reimbursement caps under recent legislation like the One Big Beautiful Bill Act, and state-level merger reviews pose risks. Macro drivers include persistent inflation in wages and supplies, workforce shortages, and policy uncertainties around Medicare Advantage. Geopolitical tensions impact supply chains, while earnings growth in pharma and providers supports resilience amid broader market cycles.

Performance and Positioning Comparison

In recent months, FHLC, IYH, and XLV exhibited comparable drawdowns amid healthcare's defensive posture, with YTD declines around -5% to -7% reflecting broader market pressures and policy overhangs. FHLC showed marginally steadier trends and lower volatility (~4.1% monthly standard deviation) due to small-cap diversification buffering large-cap swings. XLV displayed slightly higher fluctuations from concentration in mega-caps like LLY, while IYH's caps moderated extremes but higher fees eroded net returns. Over recent market cycles, broader funds like FHLC demonstrated better trend consistency versus XLV's sensitivity to top holdings. Differences stem from FHLC's inclusive scope versus XLV's large-cap focus and IYH's mid-cap tilt.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization (market cap, total value of company's shares), technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, empowering data-driven decisions across sectors like healthcare.

Tickeron AI Verdict

Tickeron’s AI favors FHLC with moderate conviction (~60% probability edge over peers) due to superior diversification (340+ holdings mitigating concentration risk), matching lowest expense ratio (0.08%), and stable momentum from broad-market exposure. While XLV excels in liquidity, FHLC's risk-adjusted positioning better suits current volatility, offering balanced upside in healthcare cycles without IYH's cost drag.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations